Výsledky vyhledávání - "Jessica R. Peachey"

A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

Autor: Kristin M Sheffield, Jessica R Peachey, Michael Method, Brenda R Grimes, Jacqueline Brown, Kim Saverno, Tomoko Sugihara, Zhanglin Lin Cui, Kimberley T Lee

Publikováno v: Future oncology (London, England). 18(21)

Aim: To assess invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, HER2-negative early breast cancer with combined clinicopathological criteria from monarchE, a phase III study of abemaciclib.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68b92d71c304b27b3b42d3dce374bcff
https://pubmed.ncbi.nlm.nih.gov/35611679

Zobrazit plný text záznamu

Recurrence risk in early breast cancer as defined by clinicopathologic features

Autor: Jessica R. Peachey, Michael Method, Jacqueline Brown, Kristin M Sheffield, Kimberley T. Lee, Yajun Emily Zhu, Brenda R. Grimes, Kim Saverno

Publikováno v: Journal of Clinical Oncology. 39:e18581-e18581

e18581 Background: While most patients (pts) with HR+, HER2- early breast cancer (EBC) do not experience disease recurrence, those with high risk clinicopathologic features may have recurrence within the first few years on adjuvant endocrine therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9c24ce3cbceb93249466152fbcd5e18
https://doi.org/10.1200/jco.2021.39.15_suppl.e18581

Zobrazit plný text záznamu

Contemporary real-world treatment patterns and outcomes of patients with advanced/metastatic hepatocellular carcinoma receiving second-line systemic therapy in the United States

Autor: Allicia C. Girvan, Kelly Rae Kirsch, Kristin M Sheffield, Jessica R. Peachey, Arjun Gupta, Mark Yarchoan, Zhanglin Lin Cui, Yongmei Chen, Elena Gonzalez Gugel

Publikováno v: Journal of Clinical Oncology. 39:279-279

279 Background: Several therapies have recently gained regulatory approval in the United States (US) as second-line (2L) treatment options for patients with advanced unresectable or metastatic hepatocellular carcinoma (HCC). Treatment patterns and as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6591e079187d2b371172295b251a4298
https://doi.org/10.1200/jco.2021.39.3_suppl.279

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání